Overview of Mefenamic

Quick Facts: Mefenamic Acid

Property	Description
Active ingredient	Mefenamic Acid
Form	Oral Capsule, Film-coated Tablet
Pharmacological class	Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use	Symptomatic relief of acute pain, inflammation, and fever
Origin	Synthetic organic compound

What Type of Medicine is Mefenamic Acid?

Mefenamic Acid is the active chemical component in the medicine known as Mefenamic, and it is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Its mechanism of action supports its inclusion in this class.

As a synthetic organic compound, Mefenamic Acid is chemically manufactured and derived from anthranilic acid, placing it within the sub-class of fenamates. Mefenamic Acid functions as a single-ingredient product, containing only the active compound combined with solid pharmaceutical excipients necessary for its structure and delivery. Its sub-classification as a fenamate provides a unique profile compared to common NSAIDs like ibuprofen, influencing its typical application in managing acute, time-limited discomfort.

Mefenamic Acid Forms and Origin

Mefenamic Acid is supplied as a solid pharmaceutical preparation for oral intake, most commonly in the form of an oral capsule or a film-coated tablet.

This medication is generally designated for short-term use for acute symptoms. Mefenamic Acid's structure provides rapid inhibitory activity against inflammatory mediators, distinguishing its acute use profile from certain NSAIDs intended for chronic therapy. This medicine is designed for prompt intervention in painful and inflammatory processes, often utilized in scenarios like the management of post-operative discomfort or other transient pain episodes.

What is the General Purpose of Mefenamic?

The general purpose of Mefenamic Acid is to provide symptomatic relief as an analgesic, an anti-inflammatory agent, and an antipyretic, addressing related physical discomforts.

The drug achieves this utility by blocking the production of prostaglandins, which are powerful chemical messengers in the body that both transmit pain signals to the brain and trigger localized inflammation. By interfering with this chemical process, Mefenamic Acid is effective in lessening the experience of acute pain, decreasing swelling and tissue irritation, and helping to reduce an elevated fever, offering a comprehensive therapeutic benefit against these interconnected symptoms.

Regulatory References

What side effects are possible with Mefenamic?

Possible Side Effects and Safety Information

The safety profile for Mefenamic Acid, an NSAID, is structured by regulatory bodies based on the frequency and severity of documented adverse reactions. The official labeling classifies effects according to the affected System-Organ Classes, principally involving Gastrointestinal, Cardiovascular, and Renal Disorders.

Adverse Reaction Classifications

Common adverse reactions, as defined in regulatory documents, frequently involve the digestive system and central nervous system. These may include diarrhea, nausea, vomiting, abdominal pain or discomfort, headache, and dizziness. Diarrhea is noted as an adverse effect that may warrant discontinuing therapy.

Serious Safety Risks

The most clinically significant safety information includes warnings for serious, potentially fatal reactions. These include:

Serious Cardiovascular Thrombotic Events: The risk of Myocardial Infarction (MI) and Stroke may increase with the duration of use.
Serious Gastrointestinal Events: Inflammation, bleeding, ulceration, and perforation of the stomach or intestines can occur at any time, sometimes without warning symptoms.
Severe Skin Reactions: Rare but serious reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are documented, typically occurring early in the course of therapy.

Population-Specific Safety Notes

The regulatory profile highlights specific constraints for certain populations. Older adults have a generally increased frequency of adverse reactions, particularly serious gastrointestinal events. Furthermore, the use of Mefenamic Acid is generally contraindicated in late-stage pregnancy due to the risk of premature closure of the fetal ductus arteriosus. Use is also restricted in patients with severe renal, hepatic, or cardiac failure, as defined in official prescribing information.

Overdose and Emergency Response

Overdose and When to Seek Help

Mefenamic Acid overdose may manifest with several officially documented clinical signs. These commonly involve gastrointestinal symptoms such as nausea, vomiting, and stomach pain, alongside central nervous system effects including drowsiness, lethargy, confusion, and tinnitus. Overdose scenarios are officially associated with a high risk of seizures and convulsions.

Severe or life-threatening outcomes documented in regulatory sources include acute renal failure, systemic shock, coma, and gastrointestinal bleeding. Due to the potential for these serious manifestations, immediate medical attention is required upon any suspected overdose. Regulators mandate that users contact a poison control center or hospital emergency department immediately, and emergency services must be called if the affected individual has collapsed or experienced a seizure.

Management procedures officially described include emptying the stomach by gastric lavage or inducing emesis, followed by the administration of activated charcoal. Since no specific antidote is known, the treatment is entirely symptomatic and supportive. Close hospital monitoring of vital functions is required, with special considerations noted for patients with underlying renal or hepatic failure and for symptomatic children.

Therapeutic Uses of Mefenamic

What Mefenamic Treats: Main Uses and Benefits

The medication is applied across domains where additional symptomatic support is needed for specific types of acute discomfort. Mefenamic Acid is generally used to help manage symptoms related to physical discomfort and heightened physiological activity. It is commonly applied in scenarios where short-term symptomatic assistance is needed for conditions presenting with acute episodes.

This medicine is considered relevant for easing symptoms associated with mild to moderate acute pain, primary dysmenorrhea (menstrual cramps), and menorrhagia (abnormally heavy menstrual bleeding). This therapeutic use contributes to easing the overall symptom load, which may assist with maintaining comfort during periods of heightened symptoms.

“Mefenamic Acid may be part of symptomatic management for both localized swelling and elevated body temperature (fever), providing support that helps ease the overall symptom burden.”

Quick Fact: Relief for Acute Discomfort

Symptom Domain	Typical Context	Patient Benefit
Spasmodic Pain	Menstrual Cramping	Supports the patient during difficult episodes by easing distress.
Acute Pain & Aches	Post-procedural, Musculoskeletal	Assists with maintaining functional stability.
Systemic Symptoms	Inflammation, Fever	Contributes to easing the overall symptom load.

Regulatory References

NIH DailyMed overview

Eligibility and Restrictions for Use

Mefenamic Acid eligibility is strictly defined by regulatory documents, distinguishing between populations permitted, restricted, or prohibited from using the medicine. General use is authorized for adults and adolescents ge14 years of age for the labeled indications.

Contraindicated Populations (Must Not Use)

Official labeling mandates that the medicine is contraindicated (must not be used) in patients with specific conditions, including:

Hypersensitivity to Mefenamic Acid, aspirin, or any other NSAID.
Active GI ulceration or chronic inflammation, such as Inflammatory Bowel Disease (IBD).
Severe organ failure (hepatic, renal, or heart failure).
Treatment of post-operative pain after Coronary Artery Bypass Graft (CABG) surgery.
Use during the last trimester of pregnancy (ge30 weeks gestation).

Population-Specific Restrictions

Population Group	Regulatory Status
Children under 14	Safety and efficacy not established; not recommended.
Older Adults (Geriatric)	Use with caution due to increased risk of serious adverse events.
Lactating Women	Not recommended (potential for adverse reaction in the infant).

Use is also highly restricted or not recommended for women attempting to conceive (due to potential fertility impairment) and for patients with certain rare hereditary metabolic disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Mefenamic Acid’s official regulatory profile defines several clinically significant interactions based on pharmacodynamic and pharmacokinetic mechanisms. The risk of gastrointestinal bleeding and ulceration is increased when co-administered with corticosteroids or Selective Serotonin Reuptake Inhibitors (SSRIs). Concurrent use with other systemic Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or anticoagulants such as Warfarin is officially discouraged or requires extreme caution due to an enhanced risk of bleeding and adverse events.

Official Interaction Statements

Pharmacokinetic documentation states that Mefenamic Acid can cause a reduction in the renal clearance of Lithium, leading to a formal elevation of plasma lithium levels. Similarly, the elimination of Methotrexate is reduced, which may result in increased exposure. For patients co-administered anti-hypertensive agents, including ACE inhibitors and Diuretics, the medicine may reduce the efficacy of those products and concurrently increase the risk of deterioration of renal function. There is a mandatory temporal restriction requiring that the medicine must not be taken for 8 to 12 days following Mifepristone administration. These interaction patterns are noted to be of increased significance in elderly patients and those with volume depletion.

Mechanism of Action

Blocking Prostaglandin Production: The Core Mechanism

Mefenamic acid acts as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes ( COX-1 and COX-2). By blocking these primary biological targets, the drug suppresses the synthesis of prostaglandins, which are key chemical mediators of localized vascular changes and afferent nerve signaling. This action modifies the chemical signaling of the underlying biological response.

Modulation of Peripheral Nociceptor and Vascular Responses

This domain addresses the resulting physiological consequences of reduced prostaglandin levels within the Arachidonic Acid Cascade. The suppressed signaling limits the sensitization of peripheral nociceptors (pain receptors) and decreases local vascular permeability, leading to physiological adjustments that include decreased sensitization of afferent nerve endings and a reduction in localized vascular fluid leakage.

Adjustment of Hypothalamic Thermoregulatory Mechanisms

This block explains the drug's effect on central pathways that control body temperature. The inhibition of prostaglandin synthesis in the brain helps reset the hypothalamic thermoregulatory center when it is elevated, which alters the elevated set point of the hypothalamic thermoregulatory center, resulting in lowered body temperature.

Dosage and Administration Information

How to Use Mefenamic Acid: Official Administration Guidelines

This section outlines the standard administration instructions for Mefenamic Acid, focusing solely on the procedural steps for proper use.

Administration Scope

Feature	Detail
Route of Administration	Oral (PO)
Dosing Schedule	Initial dose: 500 mg; Maintenance dose: 250 mg
Timing in Relation to Meals	Must be taken with food or milk to help reduce gastrointestinal irritation.
Preparation Requirements	Oral suspensions must be shaken well before measurement and administration.
Age-Group Rules	Standard dosing is for adults and adolescents (≥ 14 years old). Geriatric patients require lower initial doses.
Missed-Dose Rules	Take the missed dose as soon as possible, but do not double the dose. Skip it if it is near the next scheduled time.

Official Use Protocol

Frequency and Duration: Mefenamic Acid is taken as-needed (PRN) at a frequency of every six hours (q6hr). The treatment course is strictly limited: acute pain use generally should not exceed seven days, and use for primary dysmenorrhea is limited to two to three days.

Official Step Sequence:

Step 1: Administer the initial 500 mg dose orally.
Step 2: Follow with the 250 mg maintenance dose every 6 hours as required.
Step 3: Take each dose with food or milk.
Step 4: Cease administration after the specified short-term duration limit.

Connection to Protocol: The official protocol mandates a higher initial loading dose followed by a fixed maintenance dose at a controlled six-hour frequency, strictly defining the entire regimen. This structure, along with the requirement to administer with food, outlines the precise procedure for correct intake.

Recent Clinical Evidence

Research evidence / Overview of studies

Compound Properties and Preclinical Research

Research examined the compound's properties, which is a non-steroidal anti-inflammatory drug (NSAID). Preclinical research studied the drug's properties in laboratory settings, assessing its activity against specific biological markers. These studies explored how the compound may influence inflammatory and pain-signaling pathways.

Clinical Efficacy Trials

A systematic review examined nine randomized controlled trials (RCTs) involving thousands of participants with chronic, non-cancer-related pain. The studies primarily focused on the drug's short-term use, typically not exceeding seven days of administration.

Study Outcome Highlights

Pain Reduction: The primary endpoint in most trials evaluated the change in self-reported pain scores (e.g., using the Visual Analog Scale or VAS) over assessment periods such as 8 and 12 weeks. Research investigated the reported changes in chronic pain episodes among study participants.
Observed Response: Research examined the drug's observed time-to-response in studies. One pooled analysis documented reported changes in pain scores at specific time points following the first dose.
Quality of Life: In secondary analyses, research evaluated whether changes in patient quality of life were reported in study participants, as measured by standardized questionnaires (e.g., SF-36).

Safety and Pharmacokinetic Research

Use in Specific Populations

Population	Research Focus
Elderly Patients	Pharmacokinetic studies assessed the compound's handling (absorption, distribution, metabolism, and excretion) in adults over age 65. Trial protocols for this population were often limited to participants with normal kidney and liver function.
Renal Impairment	Studies assessed the compound's characteristics in participants with mild to moderate kidney impairment. Study design for this subgroup utilized a modified initial amount to assess the potential for compound accumulation.

Timeframe of Reported Response

Findings from clinical trials reported whether participants observed results within the first week of assessment. In that research, one large-scale Phase 3 trial documented the number of participants reporting changes in pain level by Day 7.

Frequently Asked Questions (FAQ)

Common questions about Mefenamic (FAQ)

Q: Can Mefenamic affect my blood pressure?

A: Official documentation indicates that Mefenamic Acid can potentially lead to the onset of new high blood pressure or may cause pre-existing high blood pressure to worsen. This is a possibility that has been noted in the warnings for this type of medication.

Q: Can people with stomach problems take Mefenamic?

A: Mefenamic Acid is contraindicated (must not be used) if a patient has active gastrointestinal issues like ulcers or Inflammatory Bowel Disease (IBD). For people with a history of stomach disease, official information advises caution due to the risk of the condition becoming worse.

Q: Is Mefenamic safe for older adults to use?

A: According to official drug information, Mefenamic Acid should be used with caution in older adults. This is primarily because older people are more likely to have age-related kidney problems, which might necessitate adjustments to the recommended regimen.

Q: Can Mefenamic be taken at the same time as antacids?

A: Official labeling notes a potential interaction with certain antacids, specifically those containing magnesium hydroxide. Taking Mefenamic Acid with this type of antacid may increase the level of the medicine in the body, and the potential exists for a greater risk of experiencing side effects.

Q: Can Mefenamic interfere with blood thinning medication?

A: Mefenamic Acid may enhance the response to oral anticoagulants, which are blood thinners like warfarin. This combination is associated with an increased risk of bleeding. The use of both agents may require a healthcare professional's monitoring.

Q: What are the common reasons people stop taking Mefenamic?

A: Official documents list certain adverse effects that may warrant stopping the medication. For example, severe and persistent diarrhea is specifically noted as a symptom that may require discontinuing therapy.

Q: How long does Mefenamic stay in the body after the last dose?

A: Pharmacokinetic data from regulatory sources show that the elimination half-life of the active ingredient, Mefenamic Acid, is approximately two hours in healthy adults. The half-life refers to the time it takes for half of the drug to be cleared from the bloodstream.

Q: What is Mefenamic used for besides period pain?

A: Mefenamic Acid is officially indicated for the short-term relief of mild to moderate pain from various causes. It is also approved for the treatment of menstrual cramps, which is known as primary dysmenorrhea.

Q: How quickly does Mefenamic usually start working?

A: Studies and official information indicate that peak levels of the medicine in the blood are generally reached within two to four hours after an oral dose. This timeframe suggests when the maximum therapeutic concentration is typically observed.

Q: Is it common to feel sleepy after taking Mefenamic?

A: Regulatory documents list drowsiness as a potential adverse drug reaction associated with Mefenamic Acid. Drowsiness is a nervous system effect that some patients may experience while taking the medicine.

Q: What are the main risks associated with Mefenamic?

A: The official product labeling includes serious warnings regarding cardiovascular thrombotic events, which include the risk of heart attack and stroke. There are also serious warnings about gastrointestinal events, such as bleeding, ulceration, and perforation of the stomach or intestines.

Q: Do I need a prescription to get Mefenamic?

A: According to official drug information, Mefenamic Acid is classified as a prescription-only medicine in many countries. This means its administration is generally subject to a doctor’s authorization.

Q: Is Mefenamic a type of steroid medicine?

A: No. Official documents classify Mefenamic Acid as a Nonsteroidal Anti-inflammatory Drug (NSAID). The labeling specifically states that it is not a steroid and cannot be expected to substitute for corticosteroids (steroid medicines).

Q: Can Mefenamic cause dizziness or lightheadedness?

A: Dizziness is listed as a potential side effect in the official drug information for Mefenamic Acid. If a patient experiences this, it is considered an adverse reaction.

Q: What happens if I forget to take a dose of Mefenamic?

A: Official instructions state to administer the missed dose as soon as possible. However, official guidance strictly notes that a double dose is not to be administered to compensate for the one that was missed.

Q: How long does the effect of one dose of Mefenamic last?

A: The official maintenance dosing schedule requires taking the medicine every six hours as needed. This frequency suggests the typical duration of the medicine's intended therapeutic effect aligns with this timeframe.

Q: Does taking Mefenamic with food change how it works?

A: Official instructions note that the medicine is typically administered with food or milk to help reduce irritation to the gastrointestinal tract. Regulatory documentation confirms that the effect of food on the rate of the medicine's absorption has not been fully studied.

Q: Is it true Mefenamic is only for women?

A: No. While Mefenamic Acid is often prescribed for menstrual cramps, official dosing is provided for adults and adolescents 14 years of age and older for general mild to moderate pain relief, indicating its use is not limited by gender.

Q: What is the maximum number of days Mefenamic is usually prescribed for?

A: Mefenamic Acid is intended for short-term use. For general mild to moderate pain, treatment should not exceed one week (seven days). For menstrual cramps, the treatment duration is typically limited to two to three days.

Q: Why might a doctor stop someone from taking Mefenamic?

A: Official documents list several clinical reasons for discontinuation. These include the development of severe adverse effects, such as diarrhea, or if a patient develops certain conditions, such as gastrointestinal bleeding or liver dysfunction.

Q: Are there any specific foods or drinks to avoid while taking Mefenamic?

A: Official warnings indicate that Mefenamic Acid should not be taken with alcohol. Combining the two may increase the potential risk of serious side effects, including gastrointestinal bleeding, ulceration, and perforation.

Q: Is it possible to become dependent on Mefenamic?

A: Mefenamic Acid is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is not classified as a narcotic or controlled substance with a high potential for abuse in official regulatory documents.

Q: Is Mefenamic considered a strong pain reliever?

A: According to its official indications for use, Mefenamic Acid is approved to relieve mild to moderate pain. It is not classified in regulatory sources as a medication intended for severe pain.

Q: Does Mefenamic cause fluid retention or swelling?

A: Yes, official labeling notes that fluid retention and edema (swelling) have been observed in some patients taking NSAIDs, including Mefenamic Acid.

Q: Is there research evidence supporting the use of Mefenamic for pain?

A: Yes. The basis for Mefenamic Acid's approved use is its official mechanism of action, which involves stopping the body's production of prostaglandins—substances that cause pain, fever, and inflammation.

Q: Does Mefenamic affect fertility or pregnancy planning?

A: Official information indicates that the use of NSAIDs like Mefenamic Acid is not recommended for women who are actively trying to conceive. This is due to the potential for it to impair female fertility.

Q: What is the difference between Mefenamic acid and Mefenamate?

A: Mefenamic Acid is the active chemical ingredient in the medicine. Fenamate refers to the chemical sub-class of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) that this medicine belongs to, based on its chemical structure.

Q: Do different brands of Mefenamic work exactly the same way?

A: According to regulatory standards, all legally approved brands contain the same active ingredient, Mefenamic Acid. These brands are expected to be therapeutically equivalent.

Q: Do official sources list Mefenamic as having a high potential for abuse?

A: No. Mefenamic Acid is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). It is not listed or categorized as a controlled substance with a high potential for abuse in official regulatory documents.

How should Mefenamic be stored and disposed of?

How to Store and Dispose of Mefenamic Acid

Mefenamic acid must be stored according to regulatory specifications to ensure product stability. The required storage environment is Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions. For some tablet formulations, storage should not be above 30 C.

Storage Requirements

Condition	Regulatory Requirement
Temperature	20 C to 25 C (68 F to 77 F)
Protection	Keep container tightly closed; protect from light and moisture.
Safety	Keep the medicine out of the sight and reach of children.

Disposal

Disposal instructions require that unused or expired mefenamic acid and its container be delivered to an approved waste disposal plant or handled in accordance with applicable local regulations. Environmental release, such as flushing down the toilet or pouring down a sink, must be avoided.

Mefenamic